HICE1 Inhibitors
HICE1 inhibitors encompass a variety of compounds that target microtubule dynamics, a process crucial for the function of HICE1 within the cell. Microtubules are dynamic structures that are essential for many cellular processes, including cell division, where HICE1 plays a significant role. Compounds like paclitaxel, vinblastine, and vincristine can inhibit the function of HICE1 by stabilizing or disrupting microtubules, which n turn affects the ability of HICE1 to regulate these critical cellular structures. The stabilization of microtubules by Taxol, for instance, can lead to an over-rigid microtubule network that is less dynamic and therefore less responsive to the regulatory actions of HICE1, which may rely on the ability to remodel microtubules during cell division and other processes.
Similarly, vinblastine disrupts microtubule assembly by binding to tubulin, the building block of microtubules, and preventing its polymerization. This disruption leads to the destabilization of microtubules, which compromises the normal function of HICE1, as it cannot exert its regulatory effects on non-existent or defective microtubules.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that targets a wide range of kinases. By inhibiting protein kinases that are upstream activators of HARBI1, staurosporine can decrease HARBI1 activity through reduced phosphorylation and activation of HARBI1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of the PI3K/Akt pathway. Since HARBI1 activity can be modulated by the PI3K/Akt signaling, LY294002 inhibits this pathway, potentially leading to decreased activation of HARBI1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another inhibitor of the PI3K pathway. By inhibiting PI3K, wortmannin can prevent the downstream activation of Akt and subsequently reduce the activation of HARBI1 that may be Akt-dependent. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK1/2, which are kinases in the MAPK/ERK pathway. Inhibition by U0126 can prevent ERK activation, which may be necessary for the activation of HARBI1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that acts by binding to FKBP12 and the resulting complex inhibits mTORC1. Reduced mTOR activity can lead to a decrease in HARBI1 function, as mTOR signaling is potentially a regulator of HARBI1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of the JNK signaling pathway. JNK regulates a variety of cellular functions, and its inhibition by SP600125 can decrease HARBI1 activity if HARBI1 is a downstream effector of JNK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which blocks the activation of MAPK/ERK. By inhibiting MEK, PD98059 can reduce HARBI1 activity if HARBI1 is downstream of the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A specific inhibitor of p38 MAP kinase. By blocking p38 MAP kinase activity, SB203580 can lead to decreased HARBI1 activity if HARBI1 operates downstream of the p38 MAPK pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A selective inhibitor of Src family kinases. Src kinases can regulate various signaling pathways, and their inhibition by PP2 may result in reduced activation of HARBI1 if Src kinases facilitate HARBI1 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A multi-kinase inhibitor that targets RAF kinases, among others. By inhibiting RAF, Sorafenib can reduce HARBI1 activity, assuming HARBI1 is downstream of the RAF/MEK/ERK signaling pathway. | ||||||